Aims Octreotide is a synthetic somatostatin analogue with a longer half-life. Similarto
somatostatin, octreotide is a potent inhibitor of pancreatic enzyme secretion and
effect on thecontractility of sphincter of Oddi.
Methods The present is a Double Blinded Randomised Control Study which was carried out in
the Department of Gastroenterology and a total of 75 patients were taken which were
divided into 2groups as Control (N=35) and Study group (N=40).
2 ml of normal saline and octreotide were given according to respective groups subcutaneously
1hour before procedure followed by 6 hour and 12 hours after ERCP and Serum Amylase
and Lipasewere measured along with clinical features. The following protocol was followed
based on previousstudies.
Results The overall mean age of the study population including study and control group was
52years. Most common Indications for ERCP was Choledocholithiasis (50%) followed by
malignantcause (30%), Benign Biliary Stricture (10-15%). Clinical and ERCP related
risk factors according toESGE Guidelines were present in nearly 50-60%.Hyperamylasemia
was present in Study group in 19 patients (47.5%) and amongst Control group in16 patients
(45.7%).Incidence of Post ERCP Pancreatitis was present in only 5% in study group
and 11.4% in controlgroup though statistically it was not significant (p=0.47)
Conclusions Though, there is decrease in the incidence of Post ERCP pancreatitis in the groupreceiving
octreotide, the same was not statistically significant as compared with the control
(5% vs11.4%).
